Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients
Endocrine Regulations · Ekim 2022
YÖKSİS Kayıtları
Assessment of the diagnostic performance of the 1 mg dexamethasone
suppression test in class 3 obese patients
ENDOCRINE REGULATIONS · 2022 SCOPUS, PUBMED
PROFESÖR SÜLEYMAN BALDANE →
Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients
Walter de Gruyter GmbH · 2022 Baidu Scholar Cabell's Whitelist Case CNKI Scholar (China National Knowledge Infrastructure) CNPIEC - cnpLINKer Dimensions DOAJ (Directory of Open Access Journals) EBSCO Embase ExLibris GoOA Google Scholar Japan Science and Technology Agency (JST) J-Gate JournalGuide JournalTOCs KESLI-NDSL (Korean National Discovery for Science Leaders) Medline MyScienceWork Naver Academic Naviga (Softweco) Pathway Studio Publons PubMed QOAM (Quality Open Access Market) ReadCube SCImago (SJR) SCOPUS Semantic Scholar Sherpa/RoMEO TDNet Text Mining Ulrich's Periodicals Directory/ulrichsweb WanFang Data WorldCat (OCLC) X-MOL
PROFESÖR HÜSEYİN YILMAZ →
Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients
Endocrine Regulations · 2022 scobus, embase, medline
PROFESÖR HÜSNÜ ALPTEKİN →
Makale Bilgileri
DergiEndocrine Regulations
Yayın TarihiEkim 2022
Cilt / Sayfa56 · 265-270
Scopus ID2-s2.0-85140346331
Erişim🔓 Açık Erişim
Özet
Objective. This study was aimed to evaluate the prevalence of Cushing's syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients. Methods. Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively. Results. An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing's syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing's syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl. Conclusions. The prevalence of Cushing's syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing's syndrome screening in this patient group.
Yazarlar (7)
1
Süleyman Baldane
2
Murat Celik
3
Levent Kebapcilar
4
Suleyman Hilmi Ipekci
ORCID: 0000-0003-4410-2212
5
Sedat Abusoglu
ORCID: 0000-0002-2984-0527
6
Huseyin Yilmaz
7
Husnu Alptekin
Anahtar Kelimeler
Cushing's syndrome
dexamethasone suppression test
obesity
screening
Kurumlar
Selçuk Tip Fakültesi
Konya Turkey
Metrikler
1
Atıf
7
Yazar
4
Anahtar Kelime